| CXCL9 and CXCL10 bring the heat to tumors R Reschke, TF Gajewski Science immunology 7 (73), eabq6509, 2022 | 84 | 2022 |
| Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma R Reschke, J Yu, BA Flood, EF Higgs, K Hatogai, TF Gajewski Journal for immunotherapy of cancer 9 (9), 2021 | 83 | 2021 |
| Checkpoint blockade–induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1/Tc1 Cytokines R Reschke, JW Shapiro, J Yu, SJ Rouhani, DJ Olson, Y Zha, TF Gajewski Cancer Immunology Research 10 (10), 1167-1174, 2022 | 36 | 2022 |
| Rechallenge with checkpoint inhibitors in metastatic melanoma R Reschke, M Ziemer JDDG: Journal der Deutschen Dermatologischen Gesellschaft 18 (5), 429-436, 2020 | 29 | 2020 |
| Distinct immune signatures indicative of treatment response and immune-related adverse events in melanoma patients under immune checkpoint inhibitor therapy R Reschke, P Gussek, A Boldt, U Sack, U Köhl, F Lordick, T Gora, ... International journal of molecular sciences 22 (15), 8017, 2021 | 24 | 2021 |
| Severe bullous skin eruptions on checkpoint inhibitor therapy–in most cases severe bullous lichenoid drug eruptions R Reschke, M Mockenhaupt, JC Simon, M Ziemer JDDG: Journal der Deutschen Dermatologischen Gesellschaft 17 (9), 942-948, 2019 | 24 | 2019 |
| Rechallenge of targeted therapy in metastatic melanoma R Reschke, JC Simon, M Ziemer JDDG: Journal der Deutschen Dermatologischen Gesellschaft 17 (5), 483-486, 2019 | 17 | 2019 |
| Leveraging STING, batf3 dendritic cells, CXCR3 ligands, and other components related to innate immunity to induce A “Hot” Tumor microenvironment that is responsive to immunotherapy R Reschke, DJ Olson Cancers 14 (10), 2458, 2022 | 15 | 2022 |
| Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies R Reschke, I Jäger, A Mehnert‐Theuerkauf, M Ziemer JDDG: Journal der Deutschen Dermatologischen Gesellschaft 19 (2), 215-221, 2021 | 11 | 2021 |
| Erosive Pustular Dermatosis of the Scalp: Clinicopathological Correlation Leading to a Definition of Diagnostic Criteria. R Reschke, S Grunewald, U Paasch, M Averbeck, JC Simon, T Wetzig Wounds: a Compendium of Clinical Research and Practice 33 (6), 143-146, 2021 | 9 | 2021 |
| Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction SJ Rouhani, JA Trujillo, AR Pyzer, J Yu, J Fessler, A Cabanov, EF Higgs, ... Research square, 2021 | 8 | 2021 |
| Identifying high-risk tumors within AJCC stage IB–III melanomas using a seven-marker immunohistochemical signature R Reschke, P Gussek, M Ziemer Cancers 13 (12), 2902, 2021 | 7 | 2021 |
| Risk stratification and clinical characteristics of patients with late recurrence of melanoma (> 10 years) R Reschke, K Dumann, M Ziemer Journal of Clinical Medicine 11 (7), 2026, 2022 | 6 | 2022 |
| CXCL9 and CXCL10 bring the heat to tumors. Sci. Immunol. 7, eabq6509 R Reschke, TF Gajewski | 5 | 2022 |
| Tissue-resident memory T cells in immune-related adverse events: friend or foe? R Reschke, TF Gajewski Oncoimmunology 12 (1), 2197358, 2023 | 4 | 2023 |
| Effective extracorporeal photopheresis of patients with transplantation induced acute intestinal gvHD and bronchiolitis obliterans syndrome R Reschke, S Zimmerlich, C Döhring, G Behre, M Ziemer Biomedicines 10 (8), 1887, 2022 | 3 | 2022 |
| Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors JC Stadler, L Keller, C Mess, AT Bauer, J Koett, G Geidel, I Heidrich, ... Journal for Immunotherapy of Cancer 11 (5), 2023 | 2 | 2023 |
| Gummatous Cutaneous Syphilis R Reschke, M Kunz, M Ziemer Deutsches Ärzteblatt International 119 (26), 457, 2022 | 2 | 2022 |
| Pitfall cryothermic dermatitis artefacta M Ziemer, M Kunz, M Schüürmann, D Wagenknecht, K Dumann, ... Der Hautarzt 70, 883-887, 2019 | 2 | 2019 |
| Scleroderma en coup de sabre R Reschke, V Schuster, M Kunz Deutsches Ärzteblatt International 116 (31-32), 544, 2019 | 2 | 2019 |
